health ๐ฌ BCG plus immunotherapy cuts TB relapse risk
Researchers found that combining BCG vaccination with recombinant APRIL significantly lowered tuberculosis relapse rates in preclinical studies. This study, led by scientists at the Hackensack Meridian Center for Discovery and Innovation, investigated B-cell targeting to boost TB protection. The combined treatment resulted in a 26 percent relapse rate, versus 60 percent for BCG alone. This suggests B cells are key to strengthening long-term immunity against TB recurrence. Further human trials are needed to confirm this promising therapeutic strategy. ๐ฌ